Featured Content

Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.

Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma

A patient's frailty has been determined to be associated with a higher likelihood of developing toxicities, a poor therapeutic response, and decreased survival.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

More Features>>>

Hematologic Cancers Resources

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs